Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for TEVA
54.17
+0.68 (1.27%)
Real-time:   3:15PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 53.27 - 54.95
52 week 52.62 - 72.31
Open 53.64
Vol / Avg. 8.60M/5.65M
Mkt cap 54.80B
P/E 29.75
Div/yield 0.34/2.51
EPS 1.82
Shares 1.02B
Beta 0.80
Inst. own 61%
May 9, 2016
Q1 2016 Teva Pharmaceutical Industries Ltd Earnings Call - 8:00AM EDT - Add to calendar
May 9, 2016
Q1 2016 Teva Pharmaceutical Industries Ltd Earnings Release - 7:00AM EDT - Add to calendar
Apr 18, 2016
Teva Pharmaceutical Industries Ltd Annual Shareholders Meeting
Mar 16, 2016
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference - Webcast
Mar 8, 2016
Teva Pharmaceutical Industries Ltd at Cowen Health Care Conference
Mar 3, 2016
Teva Pharmaceutical Industries Ltd at Deutsche Bank Pharma One-on-One Day
Mar 1, 2016
Teva Pharmaceutical Industries Ltd at Credit Suisse One-on-One Healthcare Conference
Feb 11, 2016
Q4 2015 Teva Pharmaceutical Industries Ltd Earnings Call - Webcast
Feb 11, 2016
Q4 2015 Teva Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 12.54% 8.74%
Operating margin 19.07% 13.85%
EBITD margin - 32.57%
Return on average assets 4.77% 3.41%
Return on average equity 7.91% 6.32%
Employees 42,888 -
CDP Score - 96 B

Address

5 Basel St., P.O. Box 3190
PETAH TIKVA, 49131
Israel
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Officers and directors

Yitzhak Peterburg Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Erez Vigodman President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Eyal Desheh Group Executive Vice President, Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Carlo De Notaristefani President and Chief Executive Officer, Global Operations
Age: 58
Bio & Compensation  - Reuters
Robert Koremans President, Chief Executive Officer - Global Specialty Medicines
Age: 54
Bio & Compensation  - Reuters
Sigurdur Oli Olafsson President and Chief Executive Officer - Global Generic Medicines Group
Age: 47
Bio & Compensation  - Reuters
Richard S. Egosi Group Executive Vice President, Chief Legal Officer
Age: 53
Bio & Compensation  - Reuters
Iris Beck-Codner Group Executive Vice President - Corporate Marketing Excellence and Communication
Age: 50
Bio & Compensation  - Reuters
Mark Sabag Group Executive Vice President, Human Resources
Age: 45
Bio & Compensation  - Reuters
Timothy R. Wright Executive Vice President, Business Development, Strategy and Commercial Innovation
Age: 58
Bio & Compensation  - Reuters